Novartis Boosts Cell Therapy Portfolio in Licensing, R&D Deal

Looking to pump up its cell therapy portfolio, Novartis Sept. 6 revealed plans to partner with Kentucky-based Regenerex for use of the company’s facilitating cell therapy (FCRx) platform. The hematopoietic stem cell-based platform has already been investigated in kidney transplantation to induce stable immunological tolerance.
Washington Drug Letter